Información del artículo
El Texto completo está disponible en PDF
References
[1.]
M.I. Costner, R.D. Sontheimer.
Lupus erythematosus.
Fitzpatrick's Dermatology in General Medicine, 6th ed., pp. 1677-1693
[2.]
G. Guhl, B. Díaz-Ley, J. Fernández-Herrera.
Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab.
Actas Dermosifiliogr, 99 (2008), pp. 5-33
[3.]
M.P. Heffernan, D.I. Smith, D. Bentley, M. Tabacchi, J.E. Graves.
A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus.
J Drugs Dermatol, 6 (2007), pp. 310-314
[4.]
T.H. Clayton, S. Ogden, M.D. Goodfield.
Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab.
J Am Acad Dermatol, 54 (2006), pp. 892-895
[5.]
N. Usmani, M. Goodfield.
Efalizumab in the treatment of discoid lupus erythematosus.
Arch Dermatol, 143 (2007), pp. 873-877
[6.]
A. Hamprecht, T. Tüting, T. Bieber, J. Wenzel.
Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab.
Clin Exp Dermatol, 33 (2008), pp. 347-348
[7.]
D.D. Bentley, J.E. Graves, D.I. Smith, M.P. Heffernan.
Efalizumab-induced subacute cutaneous lupus erythematosus.
J Am Acad Dermatol, 54 (2006), pp. S242-S243
[8.]
H. Durox, A. Sparsa, V. Loustaud-Ratti, S. Prey, G. Gondran, P. Manea, et al.
Efalizumab-induced lupus-like syndrome.
Acta Derm Venereol, 88 (2008), pp. 270-271
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
